Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Mar;65(3):405-7.
doi: 10.1136/ard.2005.037424. Epub 2005 Sep 8.

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

S Kary  1 , M Worm, H Audring, D Huscher, M Renelt, H Sörensen, E Ständer, U Maass, H Lee, W Sterry, G-R Burmester
Affiliations
Case Reports

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

S Kary et al. Ann Rheum Dis. 2006 Mar.

Abstract

Background: Blockage of tumour necrosis factor alpha (TNFalpha) is highly effective in rheumatic diseases, especially in rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Furthermore, TNFalpha antagonists have also been shown to significantly reduce psoriatic skin lesions.

Case reports: A series of nine patients with RA who were treated with different types of TNFalpha antagonists and who unexpectedly developed either a new onset or an exacerbation of psoriatic skin lesions are reported.

PubMed Disclaimer

Comment in

References

    1. Oh C J, Das K M, Gottlieb A B. Treatment with anti‐tumor necrosis factor alpha (TNF‐alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 200042829–830. - PubMed
    1. Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque‐type psoriasis: a randomised trial. Lancet 20013571842–1847. - PubMed
    1. Mease P. Psoriasis arthritis. TNFα therapy in psoriatic arthritis and psoriasis. How and why does it work? Ann Rheum Dis 200463755–758. - PMC - PubMed
    1. Iyer S, Yamauchi P, Lowe N J. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2001144118–121. - PubMed
    1. Ogilvie A L, Antoni C, Dechant C, Manger B, Kalden J R, Schuler G.et al Treatment of psoriatic arthritis with antitumour necrosis factor‐alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001144587–589. - PubMed

Publication types